

## SEQUENCE LISTING

<110> Blaschuk, Orest W.  
 Gour, Barbara J.  
 Farookhi, Riaz  
 Ali, Anmar

<120> COMPOUNDS AND METHODS FOR MODULATING CELL ADHESION

<130> 100086.401C18

<140> US

<141> 2003-08-01

<160> 101

<170> PatentIn Ver. 2.0

<210> 1

<211> 108

<212> PRT

<213> Homo sapiens

<400> 1

Asp Trp Val Ile Pro Pro Ile Asn Leu Pro Glu Asn Ser Arg Gly Pro  
 1 5 10 15

Phe Pro Gln Glu Leu Val Arg Ile Arg Ser Asp Arg Asp Lys Asn Leu  
 20 25 30

Ser Leu Arg Tyr Ser Val Thr Gly Pro Gly Ala Asp Gln Pro Pro Thr  
 35 40 45

Gly Ile Phe Ile Leu Asn Pro Ile Ser Gly Gln Leu Ser Val Thr Lys  
 50 55 60

Pro Leu Asp Arg Glu Gln Ile Ala Arg Phe His Leu Arg Ala His Ala  
 65 70 75 80

Val Asp Ile Asn Gly Asn Gln Val Glu Asn Pro Ile Asp Ile Val Ile  
 85 90 95

Asn Val Ile Asp Met Asn Asp Asn Arg Pro Glu Phe  
 100 105

<210> 2

<211> 108

<212> PRT

<213> Mus musculus

<400> 2

Asp Trp Val Ile Pro Pro Ile Asn Leu Pro Glu Asn Ser Arg Gly Pro  
 1 5 10 15

Phe Pro Gln Glu Leu Val Arg Ile Arg Ser Asp Arg Asp Lys Asn Leu  
 20 25 30

Ser Leu Arg Tyr Ser Val Thr Gly Pro Gly Ala Asp Gln Pro Pro Thr  
                   35                  40                  45

Gly Ile Phe Ile Ile Asn Pro Ile Ser Gly Gln Leu Ser Val Thr Lys  
           50                  55                  60

Pro Leu Asp Arg Glu Leu Ile Ala Arg Phe His Leu Arg Ala His Ala  
       65                  70                  75                  80

Val Asp Ile Asn Gly Asn Gln Val Glu Asn Pro Ile Asp Ile Val Ile  
                   85                  90                  95

Asn Val Ile Asp Met Asn Asp Asn Arg Pro Glu Phe  
           100                  105

<210> 3  
 <211> 108  
 <212> PRT  
 <213> Bos taurus

<400> 3  
 Asp Trp Val Ile Pro Pro Ile Asn Leu Pro Glu Asn Ser Arg Gly Pro  
       1                  5                  10                  15

Phe Pro Gln Glu Leu Val Arg Ile Arg Ser Asp Arg Asp Lys Asn Leu  
           20                  25                  30

Ser Leu Arg Tyr Ser Val Thr Gly Pro Gly Ala Asp Gln Pro Pro Thr  
           35                  40                  45

Gly Ile Phe Ile Ile Asn Pro Ile Ser Gly Gln Leu Ser Val Thr Lys  
           50                  55                  60

Pro Leu Asp Arg Glu Leu Ile Ala Arg Phe His Leu Arg Ala His Ala  
       65                  70                  75                  80

Val Asp Ile Asn Gly Asn Gln Val Glu Asn Pro Ile Asp Ile Val Ile  
                   85                  90                  95

Asn Val Ile Asp Met Asn Asp Asn Arg Pro Glu Phe  
           100                  105

<210> 4  
 <211> 108  
 <212> PRT  
 <213> Homo sapiens

<400> 4  
 Asp Trp Val Val Ala Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro  
       1                  5                  10                  15

Phe Pro Gln Arg Leu Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr  
           20                  25                  30

Lys Ile Phe Tyr Ser Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu  
           35                          40                          45  
 Gly Val Phe Ala Val Glu Lys Glu Thr Gly Trp Leu Leu Leu Asn Lys  
           50                          55                          60  
 Pro Leu Asp Arg Glu Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala  
       65                          70                          75                          80  
 Val Ser Glu Asn Gly Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile  
                           85                          90                          95  
 Ile Val Thr Asp Gln Asn Asp His Lys Pro Lys Phe  
                   100                          105

<210> 5  
 <211> 108  
 <212> PRT  
 <213> Mus musculus

<400> 5  
 Glu Trp Val Met Pro Pro Ile Phe Val Pro Glu Asn Gly Lys Gly Pro  
   1                          5                          10                          15  
 Phe Pro Gln Arg Leu Asn Gln Leu Lys Ser Asn Lys Asp Arg Gly Thr  
                   20                          25                          30  
 Lys Ile Phe Tyr Ser Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu  
           35                          40                          45  
 Gly Val Phe Thr Ile Glu Lys Glu Ser Gly Trp Leu Leu Leu His Met  
           50                          55                          60  
 Pro Leu Asp Arg Glu Lys Ile Val Lys Tyr Glu Leu Tyr Gly His Ala  
       65                          70                          75                          80  
 Val Ser Glu Asn Gly Ala Ser Val Glu Glu Pro Met Asn Ile Ser Ile  
                           85                          90                          95  
 Ile Val Thr Asp Gln Asn Asp Asn Lys Pro Lys Phe  
                   100                          105

<210> 6  
 <211> 108  
 <212> PRT  
 <213> Homo sapiens

<400> 6  
 Asp Trp Val Ile Pro Pro Ile Ser Cys Pro Glu Asn Glu Lys Gly Pro  
   1                          5                          10                          15  
 Phe Pro Lys Asn Leu Val Gln Ile Lys Ser Asn Lys Asp Lys Glu Gly  
           20                          25                          30  
 Lys Val Phe Tyr Ser Ile Thr Gly Gln Gly Ala Asp Thr Pro Pro Val

35						40						45					
Gly	Val	Phe	Ile	Ile	Glu	Arg	Glu	Thr	Gly	Trp	Leu	Lys	Val	Thr	Glu		
	50					55					60						
Pro	Leu	Asp	Arg	Glu	Arg	Ile	Ala	Thr	Tyr	Thr	Leu	Phe	Ser	His	Ala		
65					70					75					80		
Val	Ser	Ser	Asn	Gly	Asn	Ala	Val	Glu	Asp	Pro	Met	Glu	Ile	Leu	Ile		
				85					90					95			
Thr	Val	Thr	Asp	Gln	Asn	Asp	Asn	Lys	Pro	Glu	Phe						
			100					105									

```
<210> 7
<211> 108
<212> PRT
<213> Mus musculus
```

<400> 7																
Asp	Trp	Val	Ile	Pro	Pro	Ile	Ser	Cys	Pro	Glu	Asn	Glu	Lys	Gly	Glu	
1				5					10					15		
Phe	Pro	Lys	Asn	Leu	Val	Gln	Ile	Lys	Ser	Asn	Arg	Asp	Lys	Glu	Thr	
			20					25					30			
Lys	Val	Phe	Tyr	Ser	Ile	Thr	Gly	Gln	Gly	Ala	Asp	Lys	Pro	Pro	Val	
		35					40					45				
Gly	Val	Phe	Ile	Ile	Glu	Arg	Glu	Thr	Gly	Trp	Leu	Lys	Val	Thr	Gln	
	50					55					60					
Pro	Leu	Asp	Arg	Glu	Ala	Ile	Ala	Lys	Tyr	Ile	Leu	Tyr	Ser	His	Ala	
65					70					75					80	
Val	Ser	Ser	Asn	Gly	Glu	Ala	Val	Glu	Asp	Pro	Met	Glu	Ile	Val	Ile	
				85					90					95		
Thr	Val	Thr	Asp	Gln	Asn	Asp	Asn	Arg	Pro	Glu	Phe					
			100					105								

<210>	8
<211>	5
<212>	PRT
<213>	Unknown

```
<220>
<221> MOD_RES
<222> (2)-
<223> Where Xaa is any amino acid
```

```
<220>
<223> Description of Unknown Organism:  Cadherin Calcium
      Binding Motif
```

<400> 8

Asp Xaa Asn Asp Asn  
1 5

<210> 9

<211> 4

<212> PRT

<213> Unknown

<220>

<223> Description of Unknown Organism: Cadherin Calcium  
Binding Motif

<400> 9

Leu Asp Arg Glu  
1

<210> 10

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic Peptide  
with Classical Cell Adhesion Recognition Sequence

<220>

<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 10

Cys His Ala Val Cys  
1 5

<210> 11

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic  
control peptide

<220>

<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 11

Cys His Gly Val Cys  
1 5

<210> 12  
 <211> 5  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Cyclic peptide with cadherin cell adhesion recognition sequence

<220>  
 <223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 12  
 Lys His Ala Val Asp  
       1                  5

<210> 13  
 <211> 5  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Cyclic control peptide

<220>  
 <223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 13  
 Lys His Gly Val Asp  
       1                  5

<210> 14  
 <211> 5  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Cyclic peptide with cadherin cell adhesion recognition sequence

<220>  
 <223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or

ester group

<400> 14

Asp His Ala Val Lys  
1 5

<210> 15

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic  
control peptide

<220>

<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 15

Asp His Gly Val Lys  
1 5

<210> 16

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic  
peptide with classical cadherin cell adhesion  
recognition sequence

<220>

<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 16

Lys His Ala Val Glu  
1 5

<210> 17

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic  
control peptide

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 17

Lys His Gly Val Glu  
1 5

<210> 18

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic peptide with classical cadherin cell adhesion recognition sequence

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 18

Cys Val Ala His Cys  
1 5

<210> 19

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic control peptide

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 19

Cys Val Gly His Cys  
1 5

<210> 20

<211> 6

<212> PRT

<213> Artificial Sequence



<220>

<223> Description of Artificial Sequence: Cyclic peptide with classical cadherin cell adhesion recognition sequence

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 20

Cys His Ala Val Asp Cys  
1 5

<210> 21

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic control peptide

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 21

Cys His Gly Val Asp Cys  
1 5

<210> 22

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic peptide with classical cadherin cell adhesion recognition sequence

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 22

Cys Ala His Ala Val Cys  
1 5

<210> 23  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Cyclic  
control peptide

<220>  
<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 23  
Cys Ala His Gly Val Cys  
1 5

<210> 24  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Cyclic  
peptide with classical cadherin cell adhesion  
recognition sequence

<220>  
<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 24  
Cys Ala His Ala Val Asp Ile Cys  
1 5

<210> 25  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Cyclic  
control peptide

<220>  
<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 25

Cys Ala His Gly Val Asp Ile Cys  
 1 5

<210> 26

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic peptide with classical cadherin cell adhesion recognition sequence

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 26

Cys Ala His Ala Val Asp Cys  
 1 5

<210> 27

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic control peptide

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 27

Cys Ala His Gly Val Asp Cys  
 1 5

<210> 28

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic peptide with classical cadherin cell adhesion recognition sequence

<220>

<223> Cyclic Peptide may comprise N-terminal

modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 28

Cys Arg Ala His Ala Val Asp Cys  
1 5

<210> 29

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic  
control peptide

<220>

<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 29

Cys Arg Ala His Gly Val Asp Cys  
1 5

<210> 30

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic  
peptide with classical cadherin cell adhesion  
recognition sequence

<220>

<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 30

Cys Leu Arg Ala His Ala Val Cys  
1 5

<210> 31

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic

control peptide

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 31

Cys Leu Arg Ala His Gly Val Cys  
1 5

<210> 32

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic peptide with classical cadherin cell adhesion recognition sequence

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 32

Cys Leu Arg Ala His Ala Val Asp Cys  
1 5

<210> 33

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic control peptide

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 33

Cys Leu Arg Ala His Gly Val Asp Cys  
1 5

<210> 34

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic peptide with classical cadherin cell adhesion recognition sequence

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 34

Ala His Ala Val Asp Ile  
1 5

<210> 35

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic control peptide

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 35

Ala His Gly Val Asp Ile  
1 5

<210> 36

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic peptide with classical cadherin cell adhesion recognition sequence

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 36

Cys Ser His Ala Val Cys  
1 5

<210> 37  
 <211> 6  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Cyclic  
 control peptide

<220>  
 <223> Cyclic Peptide may comprise N-terminal  
 modification such as acetyl or alkoxybenzyl group  
 and/or C-terminal modifications such as amide or  
 ester group

<400> 37  
 Cys Ser His Gly Val Cys  
 1 5

<210> 38  
 <211> 6  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Cyclic  
 peptide with classical cadherin cell adhesion  
 recognition sequence

<220>  
 <223> Cyclic Peptide may comprise N-terminal  
 modification such as acetyl or alkoxybenzyl group  
 and/or C-terminal modifications such as amide or  
 ester group

<400> 38  
 Cys His Ala Val Ser Cys  
 1 5

<210> 39  
 <211> 6  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Cyclic  
 control peptide

<220>  
 <223> Cyclic Peptide may comprise N-terminal  
 modification such as acetyl or alkoxybenzyl group  
 and/or C-terminal modifications such as amide or  
 ester group

<400> 39

Cys His Gly Val Ser Cys  
1 5

<210> 40

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic peptide with classical cadherin cell adhesion recognition sequence

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 40

Cys Ser His Ala Val Ser Cys  
1 5

<210> 41

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic control peptide

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 41

Cys Ser His Gly Val Ser Cys  
1 5

<210> 42

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic peptide with classical cadherin cell adhesion recognition sequence



<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 42

Cys Ser His Ala Val Ser Ser Cys  
1 5

<210> 43

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic control peptide

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 43

Cys Ser His Gly Val Ser Ser Cys  
1 5

<210> 44

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic peptide with classical cadherin cell adhesion recognition sequence

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 44

Cys His Ala Val Ser Ser Cys  
1 5

<210> 45

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic control peptide

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 45

Cys His Gly Val Ser Ser Cys  
1 5

<210> 46

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic peptide with classical cadherin cell adhesion recognition sequence

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 46

Ser His Ala Val Ser Ser  
1 5

<210> 47

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic control peptide

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 47

Ser His Gly Val Ser Ser  
1 5

<210> 48

<211> 8  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Cyclic peptide with classical cadherin cell adhesion recognition sequence

<220>  
 <223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 48  
 Lys Ser His Ala Val Ser Ser Asp  
 1 5

<210> 49  
 <211> 8  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Cyclic control peptide

<220>  
 <223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 49  
 Lys Ser His Gly Val Ser Ser Asp  
 1 5

<210> 50  
 <211> 7  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Cyclic peptide with classical cadherin cell adhesion recognition sequence

<220>  
 <223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 50

Cys His Ala Val Asp Ile Cys  
 1 5

<210> 51  
 <211> 8  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Cyclic  
 peptide with classical cadherin cell adhesion  
 recognition sequence

<220>  
 <223> Cyclic Peptide may comprise N-terminal  
 modification such as acetyl or alkoxybenzyl group  
 and/or C-terminal modifications such as amide or  
 ester group

<400> 51  
 Cys His Ala Val Asp Ile Asn Cys  
 1 5

<210> 52  
 <211> 5  
 <212> PRT  
 <213> Unknown

<220>  
 <223> Description of Unknown Organism: Cadherin cell  
 adhesion recognition sequence bound by  
 alpha-6-beta-1 integrin

<400> 52  
 Tyr Ile Gly Ser Arg  
 1 5

<210> 53  
 <211> 10  
 <212> PRT  
 <213> Unknown

<220>  
 <223> Description of Unknown Organism: Cadherin cell  
 adhesion recognition sequence bound by N-CAM

<400> 53  
 Lys Tyr Ser Phe Asn Tyr Asp Gly Ser Glu  
 1 5 10

<210> 54  
 <211> 17  
 <212> PRT

<213> Unknown

<220>

<223> Description of Unknown Organism: N-CAM heparin sulfate binding site

<400> 54

Ile	Trp	Lys	His	Lys	Gly	Arg	Asp	Val	Ile	Leu	Lys	Lys	Asp	Val	Arg
1				5					10					15	

Phe

<210> 55

<211> 4

<212> PRT

<213> Unknown

<220>

<223> Description of Unknown Organism: Occluding cell adhesion recognition sequence

<400> 55

Leu	Tyr	His	Tyr
1			

<210> 56

<211> 8

<212> PRT

<213> Unknown

<220>

<223> Description of Unknown Organism: Claudin cell adhesion recognition sequence

<220>

<221> MOD\_RES

<222> (2)

<223> Where Xaa is either Lysine or arginine

<220>

<221> MOD\_RES

<222> (3)..(4)

<223> Where Xaa is an independently selected amino acid residue

<220>

<221> MOD\_RES

<222> (5)

<223> Where Xaa is either Serine or Alanine

<220>

<221> MOD\_RES

<222> (6)

<223> Where Xaa is either Tyrosine or Phenylalanine

<220>  
 <221> MOD\_RES  
 <222> (7)  
 <223> Where Xaa is an independently selected amino acid  
 residue

<400> 56  
 Trp Xaa Xaa Xaa Xaa Xaa Xaa Gly  
 1 5

<210> 57  
 <211> 9  
 <212> PRT  
 <213> Unknown

<220>  
 <223> Description of Unknown Organism: Nonclassical  
 cadherin cell adhesion recognition sequence

<220>  
 <221> MOD\_RES  
 <222> (1)  
 <223> Where Xaa is an independently selected amino acid  
 residue

<220>  
 <221> MOD\_RES  
 <222> (3)  
 <223> Where Xaa is an independently selected amino acid  
 residue

<220>  
 <221> MOD\_RES  
 <222> (4)  
 <223> Where Xaa is Isoleucine, Leucine or Valine

<220>  
 <221> MOD\_RES  
 <222> (5)  
 <223> Where Xaa is Aspartic Acid, Asparagine or Glutamic  
 Acid

<220>  
 <221> MOD\_RES  
 <222> (6)..(7)  
 <223> Where Xaa is an independently selected amino acid  
 residue

<220>  
 <221> MOD\_RES  
 <222> (8)  
 <223> Where Xaa is Serine, Threonine or Asparagine

<400> 57  
 Xaa Phe Xaa Xaa Xaa Xaa Xaa Gly

1

5

<210> 58  
<211> 4  
<212> PRT  
<213> Unknown

<220>

<223> Description of Unknown Organism: Representative  
claudin cell adhesion recognition sequence

<400> 58  
Ile Tyr Ser Tyr  
1

<210> 59  
<211> 4  
<212> PRT  
<213> Unknown

<220>

<223> Description of Unknown Organism: Representative  
claudin cell adhesion recognition sequence

<400> 59  
Thr Ser Ser Tyr  
1

<210> 60  
<211> 4  
<212> PRT  
<213> Unknown

<220>

<223> Description of Unknown Organism: Representative  
claudin cell adhesion recognition sequence

<400> 60  
Val Thr Ala Phe  
1

<210> 61  
<211> 4  
<212> PRT  
<213> Unknown

<220>

<223> Description of Unknown Organism: Representative  
claudin cell adhesion recognition sequence

<400> 61  
Val Ser Ala Phe  
1

```

<210> 62
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthesized
      Peptide

<220>
<221> MOD_RES
<222> (1)-
<223> BLOCKED by 9-fluorenylmethyloxycarbonyl

<220>
<221> MOD_RES
<222> (2)-
<223> tert-butyl protecting group

<220>
<221> MOD_RES
<222> (4)-
<223> tert-butyl protecting group

<220>
<221> MOD_RES
<222> (6)-
<223> t-Butoxycarbonyl protecting group

<220>
<221> MOD_RES
<222> (7)-
<223> tert-butyl protecting group

<220>
<221> MOD_RES
<222> (9)-
<223> tert-butyl protecting group

<220>
<221> MOD_RES
<222> (10)-
<223> Methoxy terminal group

<400> 62
Cys Asp Gly Tyr Pro Lys Asp Cys Lys Gly
  1             5             10

<210> 63
<211> 10
<212> PRT
<213> Artificial Sequence

<220>

```



<223> Description of Artificial Sequence: Synthesized  
Cyclic Peptide

<220>

<221> MOD\_RES

<222> (1)

<223> 9-fluorenylmethoxycarbonyl protecting group

<220>

<221> MOD\_RES

<222> (2)

<223> tert-butyl protecting group

<220>

<221> MOD\_RES

<222> (4)

<223> tert-butyl protecting group

<220>

<221> MOD\_RES

<222> (6)

<223> t-butoxycarbonyl protecting group

<220>

<221> MOD\_RES

<222> (7)

<223> tert-butyl protecting group

<220>

<221> MOD\_RES

<222> (9)

<223> tert-butyl protecting group

<220>

<221> MOD\_RES

<222> (10)

<223> Methoxy terminal group

<400> 63

Cys	Asp	Gly	Tyr	Pro	Lys	Asp	Cys	Lys	Gly
1				5					10

<210> 64

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesized  
peptide

<220>

<221> MOD\_RES

<222> (1)

<223> Residue has t-butoxycarbonyl, and Trityl or  
Acetamidomethyl protecting groups

<220>  
 <221> MOD\_RES  
 <222> (5)..(6)  
 <223> tert-butyl protecting group

<220>  
 <221> MOD\_RES  
 <222> (7)  
 <223> Trityl or acetaminomethyl protecting group

<400> 64  
 Cys Gly Asn Leu Ser Thr Cys Met Leu Gly  
     1                    5                    10

<210> 65  
 <211> 10  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthesized  
       cyclic peptide

<220>  
 <221> MOD\_RES  
 <222> (1)  
 <223> t-butoxycarbonyl protecting group

<220>  
 <221> MOD\_RES  
 <222> (5)..(6)  
 <223> tert-butyl protecting group

<400> 65  
 Cys Gly Asn Leu Ser Thr Cys Met Leu Gly  
     1                    5                    10

<210> 66  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthesized  
       peptide

<220>  
 <221> MOD\_RES  
 <222> (2)  
 <223> Residue has Acetamidomethyl or  
       tert-Acetaminomethyl or tert-butyl protecting  
       group

<220>

<221> MOD\_RES  
 <222> (6)  
 <223> Residue has Acetamidomethyl, tert-Acetamidomethyl  
 or tert-butyl protecting group

<220>  
 <221> MOD\_RES  
 <222> (9)  
 <223> AMIDATION

<400> 66  
 Cys Tyr Ile Gln Asn Cys Pro Leu Gly  
 1 5

<210> 67  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthesized  
 cyclic peptide

<220>  
 <221> MOD\_RES  
 <222> (9)  
 <223> AMIDATION

<400> 67  
 Cys Tyr Ile Gln Asn Cys Pro Leu Gly  
 1 5

<210> 68  
 <211> 5  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Cyclic  
 peptide with classical cadherin cell adhesion  
 recognition sequence

<220>  
 <223> Cyclic Peptide may comprise N-terminal  
 modification such as acetyl or alkoxybenzyl group  
 and/or C-terminal modifications such as amide or  
 ester group

<220>  
 <221> MOD\_RES  
 <222> (5)  
 <223> Where Xaa is beta,beta-dimethyl cysteine

<400> 68  
 Cys His Ala Val Xaa

1

5

<210> 69  
 <211> 10  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Cyclic  
 Peptide with classical cadherin cell adhesion  
 recognition sequence  
  
 <220>  
 <223> Cyclic Peptide may comprise N-terminal  
 modification such as acetyl or alkoxybenzyl group  
 and/or C-terminal modifications such as amide or  
 ester group  
  
 <220>  
 <221> MOD\_RES  
 <222> (2)  
 <223> Where Xaa is beta,beta-tetramethylene cysteine  
  
 <400> 69  
 Ile Xaa Tyr Ser His Ala Val Ser Cys Glu  
 1 5 10  
  
 <210> 70  
 <211> 10  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Cyclic  
 Peptide with classical cadherin cell adhesion  
 recognition sequence  
  
 <220>  
 <223> Cyclic Peptide may comprise N-terminal  
 modification such as acetyl or alkoxybenzyl group  
 and/or C-terminal modifications such as amide or  
 ester group  
  
 <220>  
 <221> MOD\_RES  
 <222> (2)  
 <223> Where Xaa is beta,beta-pentamethylene cysteine  
  
 <400> 70  
 Ile Xaa Tyr Ser His Ala Val Ser Ser Cys  
 1 5 10  
  
 <210> 71  
 <211> 9

<212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Cyclic peptide with classical cadherin cell adhesion recognition sequence

<220>  
 <223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<220>  
 <221> MOD\_RES  
 <222> (1)  
 <223> Where Xaa is beta-mercaptopropionic acid

<400> 71  
 Xaa Tyr Ser His Ala Val Ser Ser Cys  
       1                              5

<210> 72  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Cyclic peptide with classical cadherin cell adhesion recognition sequence

<220>  
 <223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<220>  
 <221> MOD\_RES  
 <222> (1)  
 <223> Where Xaa is  
       beta,beta-pentamethylene-beta-mercaptopropionic  
       acid

<400> 72  
 Xaa Tyr Ser His Ala Val Ser Ser Cys  
       1                              5

<210> 73  
 <211> 5  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Cyclic peptide with classical cadherin cell adhesion recognition sequence

<220>  
 <221> MOD\_RES  
 <222> (4)<sup>-</sup>  
 <223> Where Serine is D-Serine

<400> 73  
 His Ala Val Ser Ser  
 1 5

<210> 74  
 <211> 4  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthesized cyclic peptide

<400> 74  
 Trp Gly Gly Trp  
 1

<210> 75  
 <211> 15  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <223> Description of Artificial Sequence: Representative immunogen containing the HAV classical cadherin cell adhesion recognition sequence

<220>  
 <223> N-cadherin with HAV cell adhesion recognition sequence and flanking amino acids

<400> 75  
 Phe His Leu Arg Ala His Ala Val Asp Ile Asn Gly Asn Gln Val  
 1 5 10 15

<210> 76  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Cyclic peptide with classical cadherin cell adhesion

recognition sequence

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 76

Cys His Ala Val Asp Ile Asn Gly Cys  
1 5

<210> 77

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic peptide with classical cadherin cell adhesion recognition sequence

<220>

<223> Cyclic Peptide may comprise N-terminal modification such as acetyl or alkoxybenzyl group and/or C-terminal modifications such as amide or ester group

<400> 77

Ser His Ala Val Asp Ser Ser  
1 5

<210> 78

<211> 48

<212> PRT

<213> Unknown

<220>

<223> Description of Unknown Organism: Occludin cell adhesion recognition sequence and flanking amino acids

<400> 78

Gly Val Asn Pro Thr Ala Gln Ser Ser Gly Ser Leu Tyr Gly Ser Gln  
1 5 10 15

Ile Tyr Ala Leu Cys Asn Gln Phe Tyr Thr Pro Ala Ala Thr Gly Leu  
20 25 30

Tyr Val Asp Gln Tyr Leu Tyr His Tyr Cys Val Val Asp Pro Gln Glu  
35 40 45

<210> 79

<211> 10

<212> PRT

<213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Peptide with  
 classical cadherin cell adhesion recognition  
 sequence

<220>  
 <223> Cyclic Peptide may comprise N-terminal  
 modification such as acetyl or alkoxybenzyl group  
 and/or C-terminal modifications such as amide or  
 ester group

<400> 79  
 Leu Arg Ala His Ala Val Asp Ile Asn Gly  
 1 5 10

<210> 80  
 <211> 14  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <223> N-cadherin with HAV cell adhesion recognition  
 sequence and flanking amino acids

<400> 80  
 Arg Phe His Leu Arg Ala His Ala Val Asp Ile Asn Gly Asn  
 1 5 10

<210> 81  
 <211> 12  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <223> E-cadherin with HAV cell adhesion recognition  
 sequence and flanking amino acids

<400> 81  
 Thr Leu Phe Ser His Ala Val Ser Ser Asn Gly Asn  
 1 5 10

<210> 82  
 <211> 4  
 <212> PRT  
 <213> Unknown

<220>  
 <223> Description of Unknown Organism: Cadherin Calcium  
 Binding Motif

<220>  
 <221> VARIANT  
 <222> (1)...(4)  
 <223> Xaa is any amino acid

<400> 82



Xaa Asp Xaa Glu  
1

<210> 83  
<211> 4  
<212> PRT  
<213> Unknown

<220>  
<223> Description of Unknown Organism: Cadherin Calcium  
Binding Motif

<400> 83  
Asp Val Asn Glu  
1

<210> 84  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Cyclic Peptide  
with Classical Cell Adhesion Recognition Sequence

<220>  
<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 84  
Cys His Ala Val Cys Tyr  
1 5

<210> 85  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Cyclic Peptide  
with Classical Cell Adhesion Recognition Sequence

<220>  
<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 85  
Cys Phe Ser His Ala Val Cys  
1 5

<210> 86  
<211> 8  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic Peptide  
with Classical Cell Adhesion Recognition Sequence

<220>

<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 86

Cys Leu Phe Ser His Ala Val Cys  
1 5

<210> 87

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic Peptide  
with Classical Cell Adhesion Recognition Sequence

<220>

<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 87

Cys His Ala Val Cys Ser  
1 5

<210> 88

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic Peptide  
with Classical Cell Adhesion Recognition Sequence

<220>

<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 88

Ser Cys His Ala Val Cys  
1 5

<210> 89

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic Peptide  
with Classical Cell Adhesion Recognition Sequence

<220>

<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 89

Cys His Ala Val Cys Ser Ser  
1 5

<210> 90

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic Peptide  
with Classical Cell Adhesion Recognition Sequence

<220>

<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 90

Ser Cys His Ala Val Cys Ser  
1 5

<210> 91

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic Peptide  
with Classical Cell Adhesion Recognition Sequence

<220>

<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 91

Cys His Ala Val Cys Thr  
1 5

<210> 92

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic Peptide  
with Classical Cell Adhesion Recognition Sequence

<220>

<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 92

Cys His Ala Val Cys Glu  
1 5

<210> 93

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic Peptide  
with Classical Cell Adhesion Recognition Sequence

<220>

<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 93

Cys His Ala Val Cys Asp  
1 5

<210> 94

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic Peptide  
with Classical Cell Adhesion Recognition Sequence

<220>

<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 94

Cys His Ala Val Tyr Cys  
1 5

<210> 95

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic Peptide  
with Classical Cell Adhesion Recognition Sequence

<220>

<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 95

His Asn Cys His Ala Val Cys Tyr  
1 5

<210> 96

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic Peptide  
with Classical Cell Adhesion Recognition Sequence

<220>

<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<400> 96

His Asn Cys His Ala Val Cys  
1 5

<210> 97

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic Peptide  
with Classical Cell Adhesion Recognition Sequence

<220>

<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<220>

<221> MOD\_RES

<222> (5)

<223> Where Xaa is beta,beta-dimethyl cysteine

<400> 97

Cys His Ala Val Xaa

1 5

<210> 98  
 <211> 5  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Cyclic Peptide  
 with Classical Cell Adhesion Recognition Sequence

<220>  
 <223> Cyclic Peptide may comprise N-terminal  
 modification such as acetyl or alkoxybenzyl group  
 and/or C-terminal modifications such as amide or  
 ester group

<220>  
 <221> MOD\_RES  
 <222> (1)  
 <223> Where Xaa is beta,beta-dimethyl cysteine

<400> 98  
 Xaa His Ala Val Cys  
 1 5

<210> 99  
 <211> 6  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Cyclic Peptide  
 with Classical Cell Adhesion Recognition Sequence

<220>  
 <223> Cyclic Peptide may comprise N-terminal  
 modification such as acetyl or alkoxybenzyl group  
 and/or C-terminal modifications such as amide or  
 ester group

<400> 99  
 Cys His Ala Val Pro Cys  
 1 5

<210> 100  
 <211> 6  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Cyclic Peptide  
 with Classical Cell Adhesion Recognition Sequence

<220>  
 <223> Cyclic Peptide may comprise N-terminal  
 modification such as acetyl or alkoxybenzyl group

and/or C-terminal modifications such as amide or ester group

<400> 100

Tyr Cys His Ala Val Cys  
1 5

<210> 101

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Cyclic Peptide  
with Classical Cell Adhesion Recognition Sequence

<220>

<223> Cyclic Peptide may comprise N-terminal  
modification such as acetyl or alkoxybenzyl group  
and/or C-terminal modifications such as amide or  
ester group

<220>

<221> MOD\_RES

<222> (5)

<223> Where Xaa is beta,beta-dimethyl cysteine

<400> 101

His Asn Cys His Ala Val Cys Ser  
1 5